These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26773298)

  • 1. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
    Arima Y; Kaikita K; Ishii M; Ito M; Sueta D; Oimatsu Y; Sakamoto K; Tsujita K; Kojima S; Nakagawa K; Hokimoto S; Ogawa H
    J Thromb Haemost; 2016 Apr; 14(4):850-9. PubMed ID: 26773298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Oimatsu Y; Kaikita K; Ishii M; Mitsuse T; Ito M; Arima Y; Sueta D; Takahashi A; Iwashita S; Yamamoto E; Kojima S; Hokimoto S; Tsujita K
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28438734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy.
    Yamazaki M; Ohnishi T; Hosokawa K; Yamaguchi K; Yoneyama T; Kawashima A; Okada Y; Kitagawa K; Uchiyama S
    J Thromb Haemost; 2016 Sep; 14(9):1788-97. PubMed ID: 27328457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total Thrombus-Formation Analysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Ito M; Kaikita K; Sueta D; Ishii M; Oimatsu Y; Arima Y; Iwashita S; Takahashi A; Hoshiyama T; Kanazawa H; Sakamoto K; Yamamoto E; Tsujita K; Yamamuro M; Kojima S; Hokimoto S; Yamabe H; Ogawa H
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26811167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
    Hosokawa K; Ohnishi T; Sameshima H; Miura N; Ito T; Koide T; Maruyama I
    Thromb Haemost; 2013 Jan; 109(1):102-11. PubMed ID: 23179055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
    Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
    Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
    Hamilos M; Saloustros I; Skalidis E; Igoumenidis N; Kambouris M; Chlouverakis G; Vougia D; Loggakis I; Vardas PE; Kochiadakis G
    J Thromb Thrombolysis; 2015 Oct; 40(3):288-93. PubMed ID: 25662861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.
    Takashio S; Kaikita K; Nishi M; Morioka M; Higo T; Shiose A; Doman T; Horiuchi H; Fukui T; Tsujita K
    ESC Heart Fail; 2020 Oct; 7(5):3235-3239. PubMed ID: 32700467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals.
    Yamaguchi Y; Moriki T; Igari A; Matsubara Y; Ohnishi T; Hosokawa K; Murata M
    Thromb Res; 2013 Aug; 132(2):263-70. PubMed ID: 23777751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.